Related Experiment Video

Updated: Jun 12, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis

Vidya Ganapathy1, Rongrong Ge, Alison Grazioli

  • 1Division of Medical Oncology, Department of Internal Medicine, UMDNJRobert Wood Johnson Medical School and The Cancer Institute of New Jersey, New Brunswick, NJ, USA.

Molecular Cancer
|May 28, 2010
PubMed
Abstract

Insights

Transforming Growth Factor beta (TGF-beta) antagonists effectively reduced metastasis in basal-like breast cancer models. Inhibiting TGF-beta signaling offers a promising therapeutic strategy for both bone and lung metastases.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metastasis Research

Background:

  • Transforming Growth Factor beta (TGF-beta) is implicated in tumor invasion and metastasis.
  • Basal-like breast cancer models are crucial for understanding metastatic processes.
  • TGF-beta antagonists are being explored for their clinical utility.

Purpose of the Study:

  • To investigate the clinical utility of TGF-beta antagonists in a human metastatic basal-like breast cancer model.
  • To examine the effects of two TGF-beta pathway antagonists on MDA-MB-231 breast carcinoma cell sublines.
  • To assess the impact of TGF-beta inhibition on lung and bone metastasis.

Main Methods:

  • Utilized two TGF-beta pathway antagonists: 1D11 (monoclonal antibody) and LY2109761 (kinase inhibitor).
  • Tested antagonists on MDA-MB-231 sublines with preferential lung or bone metastasis.
  • Evaluated in vitro migration, invasiveness, and in vivo metastatic burden.

Main Results:

  • Both antagonists blocked TGF-beta-induced Smad phosphorylation in vitro.
  • Inhibitors reduced MDA-MB-231 cell migration and invasiveness.
  • Significant reduction in lung and bone metastatic burden observed in vivo.
  • TGF-beta antagonists also inhibited angiogenesis and osteoclast activity.

Conclusions:

  • TGF-beta plays a critical role in both bone and lung metastases of basal-like breast cancer.
  • Inhibiting TGF-beta signaling yields therapeutic effects regardless of metastatic tissue tropism.
  • Targeting the TGF-beta pathway presents a promising novel therapeutic approach for metastatic basal-like breast cancer.

More Related Videos

Spheroid Assay to Measure TGF-β-induced Invasion09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...